The 4th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development.
This is the industry's definitive antigen specific drug development forum.
Across 3 packed days, thought leaders from Novartis, ImCyse, Harvard Medical School, Toleranzia, Toralgen will reveal insight, data, and lessons learned from the last 12 months to enable you to hurdle the roadblocks preventing the development of clinically safe and effective antigen-specific immunotherapies for autoimmune and immune mediated disorders.
26-28 January, 2021
Drug Developers (Earlybird rates and workshops available): USD 1999.0,
Academic (Earlybird rates and workshops available): USD 1799.0,
Solution Providers (Earlybird rates and workshops available): USD 2499.0
Speakers: Charlotte Fribert, Chief Executive Officer, Toleranzia AB, Jean Van Rampelbergh, VP Clinical and Regulatory, Imcyse, Jose Carballido, Executive Director (Translational Medicine/ Preclinical Safety), Novartis, Saso Cermerski, VP and Head of Discovery and Translation Immunology, Cue Biopharma, Karsten Sauer, Vice President of Immunology, Repertoire Immune Medicines, Li Zhang, Assistant Professor Medicine-Endocrinology, Baylor College of Medicine, Matthias Von Herrath, Vice President and Senior Medical Officer, Global Chief Medical Officer, Novo Nordisk
Time: 08:00 - 18:00